Abstract
This study evaluated the impact of treatment with Buprenorphine Transdermal System (BTDS) on the health-related quality of life for patients with moderate-to-severe chronic low back pain (CLBP), and the correspondence between quality of life and pain. A multicenter, enriched, double-blind (DB), placebo-controlled, randomized trial evaluated BTDS 10 and 20 μg/hour for treatment of opioid-naïve patients with moderate-to-severe CLBP. The SF-36v2 survey, which measures 8 domains of quality of life, was administered at screening and following an open-label run-in period with BTDS and at weeks 4, 8, and 12 of the DB phase. Post hoc analyses compared SF-36v2 scores between BTDS and placebo groups during the DB phase. Condition burden was examined through comparisons with a U.S. general population sample. Correlations examined the correspondence between quality of life and pain measures. BTDS produced larger improvements than placebo at 12 weeks in all quality-of-life domains (Ps
Original language | English (US) |
---|---|
Pages (from-to) | 14-23 |
Number of pages | 10 |
Journal | Journal of Pain |
Volume | 14 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2013 |
Keywords
- Buprenorphine
- health-related quality of life
- low back pain
- opioid treatment
- transdermal delivery
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
- Neurology
- Clinical Neurology